Impact of urate-lowering therapy on quality of life indicators in patients with gout
Open Access
- 24 June 2021
- journal article
- research article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 62-68
Abstract
Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ineffectiveness and / or contraindications to the allopurinol administration.Patients and methods. The prospective, single-center study included 80 patients with gout. The follow-up period was at least 6 months of allopurinol or febuxostat (Azurix®) therapy in doses required to achieve the target UA level. When urate-lowering therapy was initiated, allopurinol 100 mg per day was prescribed, followed by dose titration (up to maximum of 900 mg per day) until the target UA level was reached (Results and discussion. After 6 months of follow-up, 70 (88%) patients received urate-lowering therapy, of whom 51 (73%) reached the target UA level. Allopurinol dosage titration required 26 patients, of whom 14 (54%) achieved the treatment goal. Due to the ineffectiveness of allopurinol, 32 patients were switched to febuxostat, which allowed to achieve normouricemia in 69% of cases. Fifteen (68%) of 22 patients who were initiated with febuxostat due to ADRs to allopurinol also achieved the target UA level. Patients who received febuxostat and reached the target UA level improved QoL indicators: role-physical functioning, bodily pain, general health, vitality and general physical well-being (pConclusion. In patients with ineffectiveness or intolerance to allopurinol, in 69% of cases febuxostat allows to achieve the target UA level and improving QoL and complience.Keywords
This publication has 34 references indexed in Scilit:
- Health-related quality of life in gout: a systematic reviewRheumatology, 2013
- Comparison between Two Generic Questionnaires to Assess Satisfaction with Medication in Chronic DiseasesPLOS ONE, 2013
- Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyHealth and Quality of Life Outcomes, 2012
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialArthritis Research & Therapy, 2010
- The Dynamics of Chronic Gout Treatment: Medication Gaps and Return to TherapyThe American Journal of Medicine, 2010
- Adherence with urate-lowering therapies for the treatment of goutArthritis Research & Therapy, 2009
- Perceptions of disease and health-related quality of life among patients with goutRheumatology, 2008
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2006
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986